Literature DB >> 15053731

Complications of endoscopic retrograde cholangiopancreatography. A study in a small ERCP unit.

J García-Cano Lizcano1, J A González Martín, J Morillas Ariño, A Pérez Sola.   

Abstract

BACKGROUNDS AND AIM: endoscopic retrograde cholangiopancreatography (ERCP) is an established procedure to drain the biliary and pancreatic ducts. Nevertheless, there are complications which seem to be more common in centers performing less than 200 ERCPs per year. Sometimes, however, due to the distribution of health resources, it is necessary to perform this technique in centers with a smaller number of procedures. We present the experience of ERCP-related complications in a small unit.
MATERIAL AND METHODS: this is a retrospective study on prospective data recorded during six years (1997-2002). In this period, two endoscopists working together performed 507 ERCPs, which yields an approximately average of 84 procedures per year.
RESULTS: in 507 ERCPs performed during this period of time, 55 complications arose (10.85%), and four patients died (0.79%) as a consequence of the procedure. There were 28 pancreatitis (5.5%), eight post-sphincterotomy bleeding events (1.6%), seven bilioduodenal perforations (1.4%), eight sepsis episodes of biliary origin (1.6%), and other 4 different complications. There were 418 (82.4%) successful ERCPs--either diagnostic or therapeutic--,which gave rise to 46 (11%) complications. There were 89 (17.6%) failed diagnostic or therapeutic ERCPs, which gave rise to 9 (10.11%) complications (p = 0.8 between both groups). Thirty five (7%) ERCPs were exclusively diagnostic and caused 6 (17%) complications. The 187 procedures performed for choledocholithiasis originated 14 (7.4%) complications, and represented the group with the lowest morbidity rate (p = 0.04).
CONCLUSIONS: the complications rate in our center is within the range of reported figures. ERCPs performed for choledocholithiasis was associated with the lowest complications rate. The risk-benefit ratio in the anticipated, purely diagnostic ERCP must be carefully weighed due to its morbidity.

Entities:  

Mesh:

Year:  2004        PMID: 15053731     DOI: 10.4321/s1130-01082004000300002

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

1.  Use of fully covered self-expanding metal stents in benign biliary diseases.

Authors:  Jesús García-Cano
Journal:  World J Gastrointest Endosc       Date:  2012-04-16

Review 2.  Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?

Authors:  Clotilde Fuentes-Orozco; Carlos Dávalos-Cobián; Jesús García-Correa; Gabriela Ambriz-González; Michel Dassaejv Macías-Amezcua; Jesús García-Rentería; Jorge Rendón-Félix; Mariana Chávez-Tostado; Lizbeth Araceli Cuesta-Márquez; Andrea Socorro Alvarez-Villaseñor; Ana Olivia Cortés-Flores; Alejandro González-Ojeda
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Dilation of benign strictures in the esophagus and colon with the polyflex stent: a case series study.

Authors:  Jesús García-Cano
Journal:  Dig Dis Sci       Date:  2007-06-13       Impact factor: 3.199

4.  Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography.

Authors:  Hector Martinez-Torres; Xochilt Rodriguez-Lomeli; Carlos Davalos-Cobian; Jesus Garcia-Correa; Juan Manuel Maldonado-Martinez; Fabiola Medrano-Muñoz; Clotilde Fuentes-Orozco; Alejandro Gonzalez-Ojeda
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

5.  Management of endoscopic retrograde cholangiopancreatography: related duodenal perforations.

Authors:  Dimitrios V Avgerinos; Omar H Llaguna; Andrew Y Lo; Joseph Voli; I Michael Leitman
Journal:  Surg Endosc       Date:  2008-10-02       Impact factor: 4.584

6.  Is ESR Important for Predicting Post-ERCP Pancreatitis?

Authors:  Amir Houshang Mohammad Alizadeh; Esmaeil Shamsi Afzali; Catherine Behzad; Mirhadi Mousavi; Dariush Mirsattari; Siavash Zafar Doagoo; Mohammad Reza Zali
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.